Tratamento do carcinoma metastático

Página do item simplificado
dc.contributor.authorVerona, Carlos Benedito
dc.contributor.authorZerati Filho, Miguel [UNESP]
dc.contributor.authorEl Ammar Müller, Márcio
dc.contributor.authorAlmeida Calado, Adriano
dc.contributor.institutionInstituto de Urologia e Nefrologia
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:21:04Z
dc.date.available2014-05-27T11:21:04Z
dc.date.issued2004-04-01
dc.description.abstractThe renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of life. At the time of presentation one third of the patients have advanced disease and about 50% of the patients that underwent radical nephrectomy have recurrence. With the mainstream implementation of imaging modalities, such as ultrasound, the incidental detection of RCC has dramatically increased in recent years. Patients with metastatic RCC without treatment have na average survival of 6 to 10 months, and only 10 to 20% can be expected to survive 2 years. Treatment for patients with advanced disease remains unsatisfactory and the metastatic renal cancer continue to present a therapeutic challenge systemic therapies employed in patients with this tumor include chemotherapy, hormonal therapy, and immunotherapy. The authors review the treatment strategies of the metastatic renal cell carcinoma (RCC).en
dc.description.affiliationDepartamento de Oncologia Instituto de Urologia e Nefrologia, São José do Rio Preto
dc.description.affiliationInstituto de Urologia e Nefrologia, São José do Rio Preto
dc.description.affiliationFaculdade de Medicina de Botucatu
dc.description.affiliationInstituto de Urologia e Nefrologia, Rua Voluntários de Sao Paulo, Sao Jose do Rio Preto - SP
dc.description.affiliationUnespFaculdade de Medicina de Botucatu
dc.format.extent222-227
dc.identifierhttp://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=2614
dc.identifier.citationRevista Brasileira de Medicina, v. 61, n. 4, p. 222-227, 2004.
dc.identifier.issn0034-7264
dc.identifier.scopus2-s2.0-2942527338
dc.identifier.urihttp://hdl.handle.net/11449/67702
dc.language.isopor
dc.relation.ispartofRevista Brasileira de Medicina
dc.relation.ispartofsjr0,101
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectImunotherapy
dc.subjectMetastasis
dc.subjectRenal cell carcinoma
dc.subjectTreatment
dc.subjectalpha interferon
dc.subjectinterleukin 2
dc.subjectage distribution
dc.subjectcancer chemotherapy
dc.subjectcancer combination chemotherapy
dc.subjectcancer hormone therapy
dc.subjectcancer immunotherapy
dc.subjectcancer incidence
dc.subjectcancer radiotherapy
dc.subjectcancer survival
dc.subjectclinical trial
dc.subjectechography
dc.subjecthuman
dc.subjectimaging
dc.subjectincidental finding
dc.subjectkidney carcinoma
dc.subjectmetastasis
dc.subjectnephrectomy
dc.subjectreview
dc.subjectsex difference
dc.subjectUnited States
dc.titleTratamento do carcinoma metastáticopt
dc.title.alternativeTreatment of the metastatic renal cell carcinomaen
dc.typeArtigo

Arquivos

Coleções

Artigos